Jason G. Gall

3.9k total citations
42 papers, 1.6k citations indexed

About

Jason G. Gall is a scholar working on Genetics, Molecular Biology and Epidemiology. According to data from OpenAlex, Jason G. Gall has authored 42 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Genetics, 15 papers in Molecular Biology and 14 papers in Epidemiology. Recurrent topics in Jason G. Gall's work include Virus-based gene therapy research (30 papers), CAR-T cell therapy research (11 papers) and Viral gastroenteritis research and epidemiology (10 papers). Jason G. Gall is often cited by papers focused on Virus-based gene therapy research (30 papers), CAR-T cell therapy research (11 papers) and Viral gastroenteritis research and epidemiology (10 papers). Jason G. Gall collaborates with scholars based in United States, Sweden and France. Jason G. Gall's co-authors include Erik Falck-Pedersen, Leslie A. Leinwand, C. Richter King, Ronald G. Crystal, Gary J. Nabel, Barney S. Graham, Douglas E. Brough, Richard A. Koup, Phillip L. Gomez and Rebecca Sheets and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Immunology and PLoS ONE.

In The Last Decade

Jason G. Gall

41 papers receiving 1.6k citations

Peers

Jason G. Gall

GENET

EPIDE

ONCOL

Lennart Holterman Netherlands

Bonnie A. Ewald United States

Diana M. Truitt United States

Jerome Custers Netherlands

Michael Kishko United States

Eric A. Weaver United States

Gerald W. Both Australia

Drew L. Lichtenstein United States

Saw See Hong France

Marcio O. Lasaro United States

Lennart Holterman Netherlands

Jason G. Gall

1.1k ×1.1

GENET

759 ×1.0

585 ×1.1

400 ×1.0

EPIDE

410 ×1.0

ONCOL

Citations per year, relative to Jason G. Gall Jason G. Gall (= 1×) peers Lennart Holterman

Countries citing papers authored by Jason G. Gall

Since Specialization

Citations

This map shows the geographic impact of Jason G. Gall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jason G. Gall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jason G. Gall more than expected).

Fields of papers citing papers by Jason G. Gall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jason G. Gall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jason G. Gall. The network helps show where Jason G. Gall may publish in the future.

Co-authorship network of co-authors of Jason G. Gall

This figure shows the co-authorship network connecting the top 25 collaborators of Jason G. Gall. A scholar is included among the top collaborators of Jason G. Gall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jason G. Gall. Jason G. Gall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yang, Yanhong, et al.. (2023). Characterization of Flu MOSAIC nanoparticle vaccine candidate using high performance size-exclusion chromatography to support vaccine process development. Vaccine. 41(15). 2534–2545. 1 indexed citations

Gall, Jason G., et al.. (2023). Quantitation of strain-specific hemagglutinin trimers in mosaic quadrivalent influenza nanoparticle vaccine by ELISA. Vaccine. 41(35). 5201–5210. 1 indexed citations

Rajan, A., B. David Persson, Lars Frängsmyr, et al.. (2018). Enteric Species F Human Adenoviruses use Laminin-Binding Integrins as Co-Receptors for Infection of Ht-29 Cells. Scientific Reports. 8(1). 10019–10019. 26 indexed citations

Cheng, Cheng, Lingshu Wang, Sung‐Youl Ko, et al.. (2015). Combination recombinant simian or chimpanzee adenoviral vectors for vaccine development. Vaccine. 33(51). 7344–7351. 15 indexed citations

Cranfield, Michael R., Grace P. Lee, A. R. Glenn, et al.. (2013). Adenoviruses isolated from wild gorillas are closely related to human species C viruses. Virology. 444(1-2). 119–123. 19 indexed citations

Johnson, Teresa R., et al.. (2013). Genetic Vaccine for Respiratory Syncytial Virus Provides Protection Without Disease Potentiation. Molecular Therapy. 22(1). 196–205. 33 indexed citations

Cheng, Cheng, Jason G. Gall, Martha Nason, et al.. (2012). Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination. PLoS ONE. 7(4). e33969–e33969. 19 indexed citations

Johnson, Matthew J., Constantinos Petrovas, Takuya Yamamoto, et al.. (2012). Type I IFN Induced by Adenovirus Serotypes 28 and 35 Has Multiple Effects on T Cell Immunogenicity. The Journal of Immunology. 188(12). 6109–6118. 37 indexed citations

Adams, William C., Cornelia Gujer, Gerald M. McInerney, et al.. (2011). Adenovirus type-35 vectors block human CD4 ⁺ T-cell activation via CD46 ligation. Proceedings of the National Academy of Sciences. 108(18). 7499–7504. 32 indexed citations

10.

Roy, Chad J., Satheesh K. Sivasubramani, J. Patrick Gorres, et al.. (2011). Aerosolized adenovirus-vectored vaccine as an alternative vaccine delivery method. Respiratory Research. 12(1). 153–153. 18 indexed citations

11.

Kahl, Christoph, Jessica Bonnell, Suja Hiriyanna, et al.. (2010). Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28. Vaccine. 28(35). 5691–5702. 40 indexed citations

12.

McVey, Duncan, Mohammed Zuber, Damodar Ettyreddy, et al.. (2010). Characterization of human adenovirus 35 and derivation of complex vectors. Virology Journal. 7(1). 276–276. 12 indexed citations

13.

Chen, Man, Jung‐San Chang, Martha Nason, et al.. (2010). A flow cytometry-based assay to assess RSV-specific neutralizing antibody is reproducible, efficient and accurate. Journal of Immunological Methods. 362(1-2). 180–184. 36 indexed citations

14.

Wang, Lingshu, Cheng Cheng, Sung‐Youl Ko, et al.. (2009). Delivery of Human Immunodeficiency Virus Vaccine Vectors to the Intestine Induces Enhanced Mucosal Cellular Immunity. Journal of Virology. 83(14). 7166–7175. 19 indexed citations

15.

Cheng, Cheng, Jason G. Gall, Martha Nason, et al.. (2009). Differential Specificity and Immunogenicity of Adenovirus Type 5 Neutralizing Antibodies Elicited by Natural Infection or Immunization. Journal of Virology. 84(1). 630–638. 57 indexed citations

16.

Hamilton, Melissa, Gordon A. Byrnes, Jason G. Gall, et al.. (2008). Alternate serotype adenovector provides long-term therapeutic gene expression in the eye.. PubMed. 14. 2535–46. 26 indexed citations

17.

Gall, Jason G., John W. Schoggins, & Erik Falck-Pedersen. (2007). Adenovirus Capsid Chimeras: Fiber Terminal Exon Insertions/Gene Replacements in the Major Late Transcription Unit. Humana Press eBooks. 130. 107–124. 1 indexed citations

18.

Cheng, Cheng, Jason G. Gall, Wing-Pui Kong, et al.. (2007). Mechanism of Ad5 Vaccine Immunity and Toxicity: Fiber Shaft Targeting of Dendritic Cells. PLoS Pathogens. 3(2). e25–e25. 65 indexed citations

19.

Lemiale, Franck, Hédi Haddada, Gary J. Nabel, et al.. (2006). Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41. Vaccine. 25(11). 2074–2084. 56 indexed citations

20.

Galimi, Francesco, et al.. (2004). Development of Ecdysone-Regulated Lentiviral Vectors. Molecular Therapy. 11(1). 142–148. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact